botiss biomaterials – Trademark Portfolio

Entity Type: 27

botiss biomaterials holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered and 2 are pending. Notable registered marks include JASON. The owner is based in Zossen.

Hauptstraße 28

Zossen 15806 , DE

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

BOTISS
BOTISS
Pending 2026
NOVAMAG
NOVAMAG
Pending 2025
JASON
JASON
Registered 2022

Trademark Classifications

botiss biomaterials's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does botiss biomaterials have?

botiss biomaterials has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 pending.

What trademark classes does botiss biomaterials file in?

botiss biomaterials files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are botiss biomaterials's most well-known trademarks?

botiss biomaterials's registered trademark portfolio includes well-known marks such as JASON. These are among 1 currently registered trademark in the portfolio.

What is botiss biomaterials's trademark registration success rate?

botiss biomaterials has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 2 applications are pending review.